vs
Alector, Inc.（ALEC）与Lakeside Holding Ltd（LSH）财务数据对比。点击上方公司名可切换其他公司
Lakeside Holding Ltd的季度营收约是Alector, Inc.的1.1倍（$7.0M vs $6.2M），Lakeside Holding Ltd同比增速更快（95.0% vs -88.5%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
ALEC vs LSH — 直观对比
营收规模更大
LSH
是对方的1.1倍
$6.2M
营收增速更快
LSH
高出183.5%
-88.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $7.0M |
| 净利润 | — | $-1.6M |
| 毛利率 | — | 27.2% |
| 营业利润率 | — | -21.3% |
| 净利率 | — | -22.6% |
| 营收同比 | -88.5% | 95.0% |
| 净利润同比 | -1696.9% | 18.7% |
| 每股收益（稀释后） | — | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECLSH
| Q4 25 | $6.2M | $7.0M | ||
| Q3 25 | $3.3M | $6.1M | ||
| Q2 25 | $7.9M | $6.3M | ||
| Q1 25 | $3.7M | $3.8M | ||
| Q4 24 | $54.2M | $3.6M | ||
| Q3 24 | $15.3M | $4.1M | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $15.9M | — |
净利润ALECLSH
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $-34.7M | $-1.4M | ||
| Q2 25 | $-30.5M | $-893.1K | ||
| Q1 25 | $-40.5M | $-1.1M | ||
| Q4 24 | $-2.1M | $-1.9M | ||
| Q3 24 | $-42.2M | $-1.3M | ||
| Q2 24 | $-38.7M | — | ||
| Q1 24 | $-36.1M | — |
毛利率ALECLSH
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率ALECLSH
| Q4 25 | — | -21.3% | ||
| Q3 25 | -1153.6% | -20.8% | ||
| Q2 25 | -433.6% | -8.9% | ||
| Q1 25 | -1216.5% | -28.2% | ||
| Q4 24 | -13.4% | -55.6% | ||
| Q3 24 | -315.7% | -32.5% | ||
| Q2 24 | -302.4% | — | ||
| Q1 24 | -275.0% | — |
净利率ALECLSH
| Q4 25 | — | -22.6% | ||
| Q3 25 | -1063.4% | -22.2% | ||
| Q2 25 | -387.7% | -14.2% | ||
| Q1 25 | -1101.6% | -28.2% | ||
| Q4 24 | -3.8% | -54.1% | ||
| Q3 24 | -275.2% | -32.7% | ||
| Q2 24 | -256.4% | — | ||
| Q1 24 | -227.0% | — |
每股收益（稀释后）ALECLSH
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.34 | $-0.09 | ||
| Q2 25 | $-0.30 | $-0.11 | ||
| Q1 25 | $-0.41 | $-0.14 | ||
| Q4 24 | $-0.02 | $-0.26 | ||
| Q3 24 | $-0.43 | $-0.18 | ||
| Q2 24 | $-0.40 | — | ||
| Q1 24 | $-0.38 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $1.6M |
| 总债务越低越好 | $10.0M | $2.4M |
| 股东权益账面价值 | $30.6M | $12.2M |
| 总资产 | $293.2M | $24.3M |
| 负债/权益比越低杠杆越低 | 0.33× | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资ALECLSH
| Q4 25 | $256.0M | $1.6M | ||
| Q3 25 | $291.1M | $4.5M | ||
| Q2 25 | $307.3M | $5.0M | ||
| Q1 25 | $354.6M | $1.5M | ||
| Q4 24 | $413.4M | $1.1M | ||
| Q3 24 | $457.2M | $2.7M | ||
| Q2 24 | $503.3M | — | ||
| Q1 24 | $562.1M | — |
总债务ALECLSH
| Q4 25 | $10.0M | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | $10.0M | $784.8K | ||
| Q3 24 | — | $589.9K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALECLSH
| Q4 25 | $30.6M | $12.2M | ||
| Q3 25 | $57.7M | $7.0M | ||
| Q2 25 | $71.2M | $2.8M | ||
| Q1 25 | $94.6M | $749.8K | ||
| Q4 24 | $126.8M | $1.6M | ||
| Q3 24 | $118.9M | $3.6M | ||
| Q2 24 | $150.6M | — | ||
| Q1 24 | $178.9M | — |
总资产ALECLSH
| Q4 25 | $293.2M | $24.3M | ||
| Q3 25 | $335.3M | $18.6M | ||
| Q2 25 | $356.4M | $14.4M | ||
| Q1 25 | $408.3M | $9.9M | ||
| Q4 24 | $468.3M | $9.8M | ||
| Q3 24 | $516.0M | $10.8M | ||
| Q2 24 | $570.7M | — | ||
| Q1 24 | $635.5M | — |
负债/权益比ALECLSH
| Q4 25 | 0.33× | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | 0.08× | 0.48× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-184.0M | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | $-184.1M | — |
| 自由现金流率自由现金流/营收 | -2951.3% | — |
| 资本支出强度资本支出/营收 | 0.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-326.5M | — |
8季度趋势，按日历期对齐
经营现金流ALECLSH
| Q4 25 | $-184.0M | $-453.5K | ||
| Q3 25 | $-32.5M | $-4.0M | ||
| Q2 25 | $-49.0M | $-483.7K | ||
| Q1 25 | $-60.8M | $-238.3K | ||
| Q4 24 | $-55.0M | $-530.2K | ||
| Q3 24 | $-50.7M | $-1.4M | ||
| Q2 24 | $-62.8M | — | ||
| Q1 24 | $-61.3M | — |
自由现金流ALECLSH
| Q4 25 | $-184.1M | — | ||
| Q3 25 | $-32.5M | — | ||
| Q2 25 | $-49.1M | $-497.4K | ||
| Q1 25 | $-60.8M | — | ||
| Q4 24 | $-55.2M | $-560.5K | ||
| Q3 24 | $-50.9M | $-1.4M | ||
| Q2 24 | $-63.1M | — | ||
| Q1 24 | $-61.9M | — |
自由现金流率ALECLSH
| Q4 25 | -2951.3% | — | ||
| Q3 25 | -997.6% | — | ||
| Q2 25 | -623.0% | -7.9% | ||
| Q1 25 | -1655.0% | — | ||
| Q4 24 | -101.8% | -15.6% | ||
| Q3 24 | -332.1% | -34.5% | ||
| Q2 24 | -418.6% | — | ||
| Q1 24 | -389.3% | — |
资本支出强度ALECLSH
| Q4 25 | 0.7% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.5% | 0.0% | ||
| Q4 24 | 0.3% | 0.8% | ||
| Q3 24 | 1.4% | 0.1% | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 3.4% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALEC
暂无分部数据
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
